Evidence map›Paper›PMID 41220510›Full record

ReviewJMA journal2025

The High-benefit Approach: A New Targeting Strategy in Precision Medicine.

Kosuke Inoue

Abstract readReview
In one paragraph

Review in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kosuke InoueDepartment of Social Epidemiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In medicine, treatment or intervention is typically prioritized for individuals at high risk of diseases or mortality. This high-risk approach, which focuses on "high-risk" patients, has been a cornerstone of clinical decision-making. Additionally, recent advancements in precision medicine, especially those using multi-omics data to assess disease risk, have frequently been framed within this approach. However, it is not always the case that individuals at high risk of disease benefit most from the treatment of interest. In this context, we previously proposed a novel targeting strategy called the "high-benefit approach." By applying machine learning technologies to data from randomized controlled trials or observational studies, this strategy allows us to identify subpopulations likely to experience substantial benefits from the treatment and to target them, rather than those who are simply at high risk of diseases. The high-benefit approach contributes not only to effective resource allocation but also to the potential mitigation of health disparities by identifying individuals with limited or no benefits and offering alternative approaches that would be effective for them. This review paper explains the overall concept of the high-benefit approach and its potential for application in healthcare literature, particularly in advancing future precision medicine and public health.

Indexed as

causal inferenceheterogeneityhigh-benefit approachmachine learningprecision medicine

Identifiers

PMID41220510
PMCPMC12598143

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.